Eurofins Bioanalytical Services develops surrogate virus neutralising antibody detection assays against SARS-CoV-2

Posted by Kristy Galkowski on Feb 17, 2021 5:54:46 PM

Eurofins BioPharma News February 2021 FINAL WEB

The world is entering a new era of the COVID-19 pandemic in which there is an increasing call for reliable antibody testing. Conventional neutralising antibody serological testing requires the use of a live virus conducted in a Biosafety Level 3 (BSL-3) laboratory, which presents challenges for COVID-
19 development programmes. An alternative approach is the use of a surrogate virus test (sVNT) that removes this obstacle and is the first neutralising antibody serology test to
receive emergency use authorisation (EUA) from the FDA. This innovative assay detects the presence of neutralising/ blocking antibodies against the SARS-CoV-2 virus, that block the interaction between the receptor-binding domain (RBD) of the viral spike glycoprotein and the ACE2 cell surface receptor.

Current testing methods, such as PCR, determine whether someone is actively infected by confirming the presence of
viral material or IgG/IgM antibodies that detect (binding and blocking) induced immune response from exposure to the
virus. Being an ELISA methodology, the in-house, fully validated surrogate virus neutralisation test (sVNT) is
amenable to high-throughput testing, at a lower analytical cost, and requires no extended validation timelines for
Eurofins’ client base. It also removes the obstacle faced by many COVID-19 development programmes, by eliminating
the requirement for a Biosafety level 3 containment.

The advantage over historic antibody IgG/IgM tests is that this new gold standard assay tests for neutralising
antibodies (versus binding antibodies), by confirming neutralising function without the need for a secondary
antibody and is isotype and species independent. As the world strives to combat the COVID-19 pandemic,
Eurofins is committed to being part of global solution by expanding capacity to develop reagent kits and investments
in nonproprietary assays to offer for industry COVID-19 analytical Nab testing.

For More Information on the latest Eurofins News, please click here

Read More

Tags: Quality, Clinical Trial, Bioanalytical Testing, Pharmaceutical, Development, Immunology, SARS-CoV-2, neutralizing antibody testing

Join Us for the 2019 DIA Annual Meeting in San Diego, CA

Posted by Jesse Gehris on Jun 3, 2019 9:15:00 AM


Read More

Tags: Central Laboratory, Quality, Clinical Trial, Drug Development, Bioanalytical Testing, Development, BioPharma, Gene Therapy

Eurofins Achieves 2019 CRO Leadership Award

Posted by Jesse Gehris on May 30, 2019 9:00:00 AM

For the 2019 CRO Leadership Awards, Life Science Leader magazine once again teamed up with Industry Standard Research (ISR) to determine the award recipients. More than 60 contract research organizations were assessed on over 20 performance metrics in ISR's annual CRO Quality Benchmarking survey. Eurofins is recognized as a recipient of these awards, exceeding customer expectations in every category.

Read More

Tags: Quality, Results, Drug Development, Bioanalytical Testing, Development, BioPharma

Flow Cytometry Interview with Expert David Lanham

Posted by Kristy Galkowski on May 10, 2019 2:17:07 PM
Expert Interview

In this Bioanalysis Zone interview, David Lanham of Eurofins BioPharma Services discusses flow cytometry for pharmacodynamic biomarker analysis and receptor engagement in early clinical stage work. David also explains the challenges faced when using flow cytometry as an analytical tool, before sharing his thoughts on the progress that has been made to regulate and standardize the field.

Read More

Tags: Bioanalytical Testing, BioPharma, Leadership, Flow Cytometry, Biomarker Analysis, Receptor Engagement

What is Flow Cytometry?

Posted by Kristy Galkowski on Apr 29, 2019 12:10:33 PM

Read More

Tags: Bioanalytical Testing, Cellular Response, Development, BioPharma, Immunology, Flow Cytometry

New Quanterix® SR-X™ Technology

Posted by Kristy Galkowski on Mar 12, 2019 10:26:15 AM

Eurofins Bioanalytical Services expands its technology footprint with the addition of Quanterix® SR-X™. The Ultra-Sensitive Biomarker Detection, for the bench-top. Experience the unrivaled power of Simoa® single molecule digital detection technology now available in a compact size with increased workflow flexibility.

Read More

Tags: Bioanalytical Testing, BioPharma, Quanterix, Technology

Join Us at the 13th WRIB Conference

Posted by Kristy Galkowski on Mar 8, 2019 3:02:02 PM

Eurofins BioPharma Services is once again excited to sponsor and join over 1,000 professionals at the upcoming 13th WRIB conference in New Orleans from April 1-5, 2019.

Read More

Tags: Bioanalytical Testing, Development

Global Leader in Biologics-focused Bioanalytical Solutions

Stay in the know and up-to-date on the latest Bioanalytical news, tips, and helpful links

  • Gain insight into the latest technology in the field
  • Focus on clinical research and laboratory services
  • Learn more about Biologics done right

Subscribe to Email Updates

Recent Posts